Group 1 - Baiyunshan Holdings' subsidiary Guangzhou Pharmaceutical Co., Ltd. will be listed on the New Third Board starting May 20, 2025, marking a significant step in capital operations for Baiyunshan [1] - The listing is expected to broaden financing channels and enhance brand influence, as Guangzhou Pharmaceutical is a leading pharmaceutical distribution company in South China [1] - However, the New Third Board has relatively low liquidity, necessitating the optimization of governance structures and strengthening of profitability to attract long-term capital [1] Group 2 - Dezhan Health has signed a cooperation framework agreement with Academician Yang Baofeng to establish an academician expert workstation at its subsidiary, Deyi Pharmaceutical Co., Ltd. [2] - This collaboration aims to enhance the company's drug development capabilities in the cannabinoid innovation drug field [2] - The development of cannabinoid drugs is noted to have long cycles and strict regulations, requiring attention to clinical progress and commercialization capabilities [2] Group 3 - BeiGene has registered a Phase Ib clinical trial for BGB-16673, a BTK degrader targeting chronic spontaneous urticaria, marking it as the first autoimmune disease trial for this drug [3] - BGB-16673 is the fastest progressing BTK degrader in clinical development and has the potential to address resistance issues associated with existing BTK inhibitors [3] - The expansion into autoimmune indications opens up broader market opportunities and validates the application potential of the CDAC platform across multiple disease areas [3]

为进一步强化德展大健康股份有限公司（以下简称"公司"）科研能力、提 升研发效率，前期公司与中国工程院杨宝峰院士签署了《合作框架协议》，计划 开展全方位技术合作并拟共同在公司所属企业成立院士专家工作站，有关情况详 见公司于 2024 年 12 月 19 日在巨潮资讯网（www.cninfo.com.cn）等指定信息披 露媒体上披露的《关于公司与杨宝峰院士签署 <合作框架协议> 的公告》（公告编 号：2024－070）。 证券代码：000813 证券简称：德展健康 公告编号：2025-037 德展大健康股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、基本情况 本次院士专家工作站的获批是公司全面加速落地研发创新驱动战略的重要 举措，有利于公司开拓药物研发新路径，全面提升研发能力、吸引高端人才并构 建人才高地、促进研发成果转化从而丰富公司在研及产品管线。 本次院士专家工作站的正式获批，不会对公司短期的财务状况和经营业绩构 成重大影响，敬请投资者注意投资风险。 四、备查文件 （一）北京市科学技术协会下发的《关于批准建立德义制药有限公司院士专 家工作站的 ...

一、基本情况 为进一步强化德展大健康股份有限公司（以下简称"公司"）科研能力、提 升研发效率，前期公司与中国工程院杨宝峰院士签署了《合作框架协议》，计划 开展全方位技术合作并拟共同在公司所属企业成立院士专家工作站，有关情况详 见公司于 2024 年 12 月 19 日在巨潮资讯网（www.cninfo.com.cn）等指定信息披 露媒体上披露的《关于公司与杨宝峰院士签署<合作框架协议>的公告》（公告编 号：2024－070）。 二、进展情况 近日，公司收到北京市科学技术协会（以下简称"北京市科协"）下发的《关 于批准建立德义制药有限公司院士专家工作站的通知》，北京市科协经研究批准 在公司控股子公司德义制药有限公司（以下简称"德义制药"）建立院士专家工 作站。 根据双方签署的《合作框架协议》，后续公司将与杨宝峰院士一道，依托院 士专家工作站，共同推动公司在大麻素创新药领域药品研发工作；同时着力发挥 院士专家工作站智囊及人才磁石作用，加速推动公司创新战略落实、创新药项目 研发进度、搭建科技创新平台、加快人才培养/引进、高层次技术交流。 证券代码：000813 证券简称：德展健康 公告编号：2025-037 德展大 ...

| 代码 名称 | 现价 | 涨跌 涨幅↓ | | --- | --- | --- | | 300255 常山药业 | 13.78 | +2.30 +20.03% | | 300363 博腾股份 | 29.64 | +4.18 +16.42% | | 002038 双鹭药业 | 11.74 | +1.07 +10.03% | | 000813 德展健康 | 4.54 | +0.41 +9.93% | | 688166 博瑞医药 | 29.39 | +2.29 +8.45% | | 688076 诺泰牛物 | 39.66 | +2.97 +8.09% | | 301393 吴帆生物 | 78.79 | +4.59 +6.19% | | 600721 百花医药 | 8.47 | +0.47 +5.88% | | 605116 奥锐特 | 23.01 | +1.20 +5.50% | | 301092 争光股份 | 32.62 | +1.24 =+1.95% | 自9月8日以来，医药各细分板块进入稳步上行阶段，其中涨幅最大的减肥药板块，14个交易日内涨超 22%。 今日，医药板块情绪格外高涨。 A股方面，CRO概念 ...

Core Viewpoint - The announcement details the progress of the fifth auction of shares held by a major shareholder, Shanghai Yueye, which involves 323,800,000 unrestricted circulating shares of Dezhang Health, accounting for 15.18% of the company's total share capital [1][2]. Group 1: Auction Details - The auction of 323,800,000 shares by Shanghai Yueye was conducted on the JD Judicial Auction platform, with the auction results indicating that 124,600,010 shares were successfully bid, representing 5.76% of the company's total share capital [4][6]. - The auction was held from May 15 to May 16, 2025, and the successful bidders included 13 individuals, although their relationships and future arrangements remain unknown to the company [1][2][8]. - The total amount for the successfully auctioned shares was approximately 355,110,028.50 yuan [5]. Group 2: Shareholder Impact - Following the auction, if the transfer of shares is completed, Shanghai Yueye's holdings will decrease to 199,199,990 shares, which will represent 9.20% of the company's total share capital [7]. - The successful bidder, Chen Zhiwenlong, will become a shareholder holding more than 5% of the company, and the company will ensure compliance with relevant disclosure obligations [7][8]. Group 3: Previous Auctions - Prior to this auction, Shanghai Yueye had conducted multiple auctions, with a total of 214,938,076 shares auctioned cumulatively, accounting for 9.93% of the company's total share capital [6][7]. - The previous auctions included a successful bid for 65,088,066 shares in the fourth auction, which was completed in April 2025 [6].

证券代码：000813 证券简称：德展健康 公告编号：2025-036 德展大健康股份有限公司 关于变更办公地址的公告 公司董事会秘书和证券事务代表联系地址同步变更为上述新办公地址。除上 述变更内容外，公司注册地址、投资者咨询电话、传真号码、电子邮箱、公司网 址等其他联系方式均保持不变。 以上办公地址自本公告发布之日起正式启用，敬请广大投资者关注，由此带 来的不便，敬请谅解。 特此公告。 德展大健康股份有限公司董事会 二〇二五年五月十七日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 德展大健康股份有限公司（以下简称"公司"）因经营发展需要，于近日搬 迁至新办公地址，现将变更情况公告如下: | 变更事项 | 变更前 | 变更后 | | | --- | --- | --- | --- | | 办公地址 | 北京市朝阳区工体东路 | 北京市朝阳区亮马桥路 | 39 | | | 乙 2 号博纳大厦 10 层 | 号第一上海中心 C 座 7 | 层 | | 邮政编码 | 100027 | 100125 | | ...

证券代码：000813 证券简称：德展健康 公告编号：2025-034 德展大健康股份有限公司 关于持股 5%以上股东所持公司股份第五次拍卖的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 2、上海岳野不是公司控股股东或实际控制人，其所持有的公司股份被 拍卖不会导致公司控制权发生变化，不会对公司的正常生产经营产生不利 影响。 3、本次拍卖的 323,800,000 股股份中的 124,600,010 股股份被竞拍成 功 ， 竞 买 人 为 陈 致 文 龙 、 陆 静 波 、 仉 凤 梧 等 13 名 自 然 人 ； 剩 余 199,199,990 股股份因在规定时间内无人出价未能竞拍成功。截至本公告 披露日，公司未知竞买人之间关系，以及是否为一致行动人和后续安排。 本次拍卖事项尚涉及缴纳竞拍余款、股权过户登记等环节，存在一定的不 确定性。公司将持续关注本次拍卖的后续进展情况并及时履行信息披露义 务。 公司于 2025 年 5 月 6 日在巨潮资讯网（www.cninfo.com.cn）等指定信息 披露媒体披露了《关于持股 5%以上股东所持 ...

网上集体接待日活动的公告 证券代码：000813 证券简称：德展健康 公告编号：2025-035 德展大健康股份有限公司 关于参加新疆辖区上市公司 2025 年投资者 特此公告。 德展大健康股份有限公司董事会 二〇二五年五月十七日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，德展大健康股份有限公司（以下简称"公 司"）将参加由新疆上市公司协会根据新疆证监局工作部署，联合深圳市全景网 络有限公司举办的"2025 年新疆辖区上市公司投资者网上集体接待日活动"，现 将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 5 月 23 日（周五）15:00-17:30。届时 公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、融资 计划和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投 资者踊跃参与！ ...

Industry Overview - The cholesterol-lowering drug industry is crucial for preventing and treating cardiovascular diseases, with a growing patient population due to aging and increasing rates of dyslipidemia [1][8] - The prevalence of dyslipidemia among the elderly is high, with 47% of individuals over 60 affected, while the rate among those aged 18 and above has risen from 18.6% in 2002 to 35.6% in 2023 [8][10] Market Development - The cholesterol-lowering drug market in China is projected to grow from CNY 252.94 billion in 2023 to CNY 265.95 billion in 2024, despite a slowdown due to national procurement policies [10][20] - Sales distribution shows that 57% of sales come from hospitals, while 43% are from retail markets [10] Drug Categories - Cholesterol-lowering drugs are categorized into statins, fibrates, niacin, bile acid sequestrants, PCSK9 inhibitors, and monoclonal antibodies targeting angiopoietin-like protein 3 [3][12] - Statins dominate the market with a 76.58% share, but innovative drugs like PCSK9 inhibitors are gaining traction [12][22] Competitive Landscape - The market is experiencing significant changes, with foreign companies like Pfizer and Sanofi leading the high-end market, while local firms like Yuyuan Health and Jingxin Pharmaceutical focus on mid to low-end markets [14][16] - Competition is shifting from price to efficacy, safety, and brand service, with an expected increase in market concentration through mergers and international collaborations [14][22] Company Highlights - Jingxin Pharmaceutical focuses on the development and sales of statins and is expanding into combination therapies and new drug targets [16] - Yuyuan Health has developed a PCSK9-targeting siRNA drug, YKYY015, which is in clinical trials and has received IND approval in the U.S. [18] - The revenue of Yuyuan Health is projected to decline by 9.9% in 2024, with cardiovascular drug sales down by 20.73% [18] Future Trends - The market for cholesterol-lowering drugs is expected to continue expanding due to an increasing patient population and unmet treatment needs, with projections indicating a compound annual growth rate above a certain percentage [20][21] - Innovation in drug development is on the rise, with companies investing in new targets like Lp(a) and PCSK9 inhibitors, enhancing treatment options for patients [21][22]

Group 1: Research and Development - The company has 4 specialized pharmaceutical research institutions and 1 postdoctoral workstation, with a research team of approximately 200 people, accounting for about 20% of total employees. In 2024, R&D investment is expected to be 16.76% of sales revenue [1] - The WYY project is a novel compound with over 20 intellectual property applications globally, demonstrating superior efficacy and safety compared to competitors in animal studies. It is currently in the preclinical research stage, with an IND application planned for submission within the year [2] Group 2: Project Updates - The Wuhan Psychological Rehabilitation Hospital project received its medical institution practice license by the end of December 2024, aiming to operate as a tertiary specialized hospital [4] - The company is advancing the production line for recombinant collagen, with stable production processes meeting industry standards, and is preparing for large-scale production [6] Group 3: Market and Financial Insights - The gross profit margin for the company's main product, "A Le," has remained around 60% despite the impact of centralized procurement policies [8] - The company is considering external licensing for the WYY project based on clinical trial progress and commercialization conditions [3] Group 4: Future Developments - The company is focusing on developing CBD for treating pulmonary arterial hypertension, with a significant unmet market demand, as there are approximately 12 million patients in China [7][8] - VGX-3100, a key project of a major associate company, is undergoing phase III clinical trials for HPV-related cervical lesions, with plans to complete participant enrollment by 2025 [8]